Day One Biopharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
06/05/2025 22:01
Day One Biopharmaceuticals Inc DAWN.OQ reported a quarterly adjusted loss of 35 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -72 cents. The mean expectation of eight analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -73 cents to -33 cents per share. Revenue was $30.76 million; analysts expected $30.24 million. Day One Biopharmaceuticals Inc's reported EPS for the quarter was a loss of 35 cents. The company reported a quarterly loss of $36 million. Day One Biopharmaceuticals Inc shares had fallen by 5.7% this quarter and lost 41.0% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 40% in the last three months. In the last 30 days, two analysts negatively revised earnings estimates RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $30.00 This summary was machine generated from LSEG data May 6 at 09:01 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.44 | -0.35 | Beat |
| Dec. 31 2024 | -0.36 | -0.64 | Missed |
| Sep. 30 2024 | -0.41 | -0.37 | Beat |
| Jun. 30 2024 | -0.75 | -0.05 | Beat |